Effects of Negative Energy Balance on Muscle Mass Regulation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI > 27 kg/m2 (adults)
- postmenopausal state
Exclusion criteria:
- weight loss of more than 5kg in the last 2 months x
- unhealthy patients with: severe chronic diseases including cancer within the last 5 years, severe heart disease, severe impairment of hepatic or renal function, severe anaemia or disturbed coagulation
- eating disorders or any other psychiatric condition that would interact with the trial intervention
- malabsorption
- acute or chronic infections
- severe hypertension
- myopathy
- food allergies
- any other uncontrolled endocrine disorder
- changes of smoking habits, diets or medication that strongly affects energy homeostasis within the last 3 months prior to study inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
|
no intervention, only follow up
|
|
Active Comparator: lifestyle intervention
Multimodal lifestyle intervention to reduce body weight
|
multimodal lifestyle intervention will be performed to reduce body weight
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of myocellular insulin sensitivity (hyperinsulinemic clamp) during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 4 months
|
Analysis of myocellular insulin sensitivity by hyperinsulinemic clamp in mg•kg-1•min-1/(mU•L-1)
|
4 months
|
|
Changes of skeletal muscle mass (air displacement plethysmography) during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 4 months
|
Analysis of muscle mass (in % of body weight)
|
4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effects on energy expenditure
Time Frame: 4 months
|
Measurement of energy expenditure (kcal/d), postprandial thermogenesis (%) and respiratory coefficient
|
4 months
|
|
Effects on myocellular and adipose tissue metabolism and substrate utilization
Time Frame: 4 months
|
Measurement of myocellular and adipose metabolism using microdialysis (glycerol (µmol/l), lactate (mmol/l), pyruvate (µmol/l), glucose (mmol/l)) during oral glucose load (180 minutes)
|
4 months
|
|
Effects on myocellular and adipose tissue mRNA expression
Time Frame: 4 months
|
Analysis of myocellular and adipose mRNA expression (RNA sequencing) in counts
|
4 months
|
|
Weight regain
Time Frame: 24 months
|
Analysis of body weight regain (BMI; kg/m2) during follow up
|
24 months
|
|
Fat mass
Time Frame: 24 months
|
Analysis of body fat (kg and %)
|
24 months
|
|
Measurement of human gut microbiome at baseline, during weight loos, after weight loss (negative energy balance) and during stabilized modification of body composition 4 weeks after weight loss
Time Frame: 4 months
|
16S rRNA sequencing and/or shotgun metagenomic pyrosequencing of the gut microbiota for assessment of microbiota composition and gene abundances.
|
4 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FFA during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 12 months
|
Measurement of fatty acids at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.
|
12 months
|
|
Metanephrines during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 12 months
|
Measurement of metanephrines at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.
|
12 months
|
|
Leptin during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 12 months
|
Measurement of leptin at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.
|
12 months
|
|
Cortisol during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 12 months
|
Measurement of cortisol at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.
|
12 months
|
|
Follistatin during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 12 months
|
Measurement of follistatin at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.
|
12 months
|
|
Adiponectin during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 12 months
|
Measurement adiponectin at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.
|
12 months
|
|
Natriuretic peptide during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 12 months
|
Measurement of natriuretic peptide at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.
|
12 months
|
|
IGF-1 during negative energy balance and during stabilized modification of body composition after weight loss.
Time Frame: 12 months
|
Measurement of IGF-1 at baseline, during negative energy balance, during stabilized modification of body composition after weight loss and during follow up.
|
12 months
|
|
Analysis of predictive impact of several hormonal and metabolic parameters on body weight regain, course of insulin sensitivity and metabolism
Time Frame: 24 months
|
The effect of measured parameters (see other endpoints) on long-term course of BMI, muscle mass, insulin sensitivity and energy expenditure will be analyzed using mathematical models
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Koppel N, Bisanz JE, Pandelia ME, Turnbaugh PJ, Balskus EP. Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. Elife. 2018 May 15;7:e33953. doi: 10.7554/eLife.33953.
- Sbierski-Kind J, Grenkowitz S, Schlickeiser S, Sandforth A, Friedrich M, Kunkel D, Glauben R, Brachs S, Mai K, Thurmer A, Radonic A, Drechsel O, Turnbaugh PJ, Bisanz JE, Volk HD, Spranger J, von Schwartzenberg RJ. Effects of caloric restriction on the gut microbiome are linked with immune senescence. Microbiome. 2022 Apr 4;10(1):57. doi: 10.1186/s40168-022-01249-4.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EA 20100415
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.